Novo Nordisk Revenue 2006-2019 | NVO

Novo Nordisk annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Novo Nordisk revenue for the quarter ending September 30, 2019 was $4.511B, a 4.17% increase year-over-year.
  • Novo Nordisk revenue for the twelve months ending September 30, 2019 was $17.427B, a 1.05% decline year-over-year.
  • Novo Nordisk annual revenue for 2018 was $17.099B, a 0.78% increase from 2017.
  • Novo Nordisk annual revenue for 2017 was $16.967B, a 2.14% increase from 2016.
  • Novo Nordisk annual revenue for 2016 was $16.611B, a 3.43% increase from 2015.
Novo Nordisk Annual Revenue
(Millions of US $)
2018 $17,099
2017 $16,967
2016 $16,611
2015 $16,060
2014 $15,834
2013 $14,884
2012 $13,483
2011 $12,400
2010 $10,836
2009 $9,567
2008 $8,974
2007 $7,697
2006 $6,509
2005 $5,638
Novo Nordisk Quarterly Revenue
(Millions of US $)
Q3 2019 $4,511
Q2 2019 $4,523
Q1 2019 $4,458
Q4 2018 $3,934
Q3 2018 $4,331
Q2 2018 $4,388
Q1 2018 $4,446
Q4 2017 $4,446
Q3 2017 $4,205
Q2 2017 $4,236
Q1 2017 $4,080
Q4 2016 $4,284
Q3 2016 $4,131
Q2 2016 $4,171
Q1 2016 $4,025
Q4 2015 $4,234
Q3 2015 $3,995
Q2 2015 $4,010
Q1 2015 $3,820
Q4 2014 $4,161
Q3 2014 $3,960
Q2 2014 $3,975
Q1 2014 $3,737
Q4 2013 $3,957
Q3 2013 $3,643
Q2 2013 $3,746
Q1 2013 $3,539
Q4 2012 $3,653
Q3 2012 $3,336
Q2 2012 $3,364
Q1 2012 $3,130
Q4 2011 $3,211
Q3 2011 $3,093
Q2 2011 $3,088
Q1 2011 $2,878
Q4 2010 $2,978
Q3 2010 $2,905
Q2 2010 $2,721
Q1 2010 $2,451
Q4 2009 $2,586
Q3 2009 $2,483
Q2 2009 $2,379
Q1 2009 $2,223
Q4 2008 $2,227
Q3 2008 $2,272
Q2 2008 $1,489
Q1 2008 $2,133
Q4 2007 $2,124
Q3 2007 $1,943
Q2 2007 $1,912
Q1 2007 $1,726
Q4 2006 $2,004
Q3 2006 $1,596
Q2 2006 $1,117
Q1 2006 $1,441
Q4 2005 $1,660
Q3 2005 $1,507
Q2 2005 $1,414
Q1 2005 $1,279
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $134.360B $17.724B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.462B 16.01
Roche Holding AG (RHHBY) Switzerland $264.146B 0.00
Merck (MRK) United States $226.211B 17.52
Pfizer (PFE) United States $211.902B 12.60
Novartis AG (NVS) Switzerland $211.006B 17.81
AbbVie (ABBV) United States $128.628B 10.08
AstraZeneca (AZN) United Kingdom $125.101B 22.60
Sanofi (SNY) France $115.265B 14.16
Eli Lilly (LLY) United States $114.870B 21.21
GlaxoSmithKline (GSK) United Kingdom $113.512B 13.75
Bristol-Myers Squibb (BMY) United States $97.676B 13.66
Bayer (BAYRY) Germany $71.322B 10.56
H Lundbeck (HLUYY) Denmark $7.591B 10.95